Synovus Financial Corp bought a new position in shares of AstraZeneca plc (NYSE:AZN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 9,417 shares of the company’s stock, valued at approximately $327,000.
Several other large investors also recently modified their holdings of AZN. The Manufacturers Life Insurance Company boosted its stake in shares of AstraZeneca by 9.9% during the second quarter. The Manufacturers Life Insurance Company now owns 14,713 shares of the company’s stock valued at $502,000 after purchasing an additional 1,327 shares in the last quarter. M&T Bank Corp boosted its stake in shares of AstraZeneca by 0.5% during the fourth quarter. M&T Bank Corp now owns 317,119 shares of the company’s stock valued at $11,003,000 after purchasing an additional 1,676 shares in the last quarter. TIAA FSB boosted its stake in shares of AstraZeneca by 6.7% during the fourth quarter. TIAA FSB now owns 27,087 shares of the company’s stock valued at $940,000 after purchasing an additional 1,692 shares in the last quarter. First Allied Advisory Services Inc. boosted its stake in shares of AstraZeneca by 7.6% during the fourth quarter. First Allied Advisory Services Inc. now owns 23,845 shares of the company’s stock valued at $825,000 after purchasing an additional 1,694 shares in the last quarter. Finally, Trustmark National Bank Trust Department boosted its stake in shares of AstraZeneca by 14.1% during the third quarter. Trustmark National Bank Trust Department now owns 14,197 shares of the company’s stock valued at $481,000 after purchasing an additional 1,752 shares in the last quarter. 14.91% of the stock is currently owned by institutional investors and hedge funds.
AZN has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Monday, January 22nd. BMO Capital Markets set a $38.00 price objective on shares of AstraZeneca and gave the company a “buy” rating in a research note on Wednesday, January 10th. Sanford C. Bernstein increased their price objective on shares of AstraZeneca from $40.00 to $42.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Leerink Swann reiterated a “market perform” rating and set a $36.00 price objective (up from $33.00) on shares of AstraZeneca in a research note on Thursday, January 18th. Finally, JPMorgan Chase & Co. upgraded shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a research note on Friday, December 29th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $36.26.
Shares of AstraZeneca plc (NYSE:AZN) opened at $34.01 on Friday. The firm has a market cap of $85,329.70, a P/E ratio of 14.35, a price-to-earnings-growth ratio of 2.04 and a beta of 0.70. AstraZeneca plc has a one year low of $28.43 and a one year high of $36.70. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.93.
AstraZeneca (NYSE:AZN) last announced its earnings results on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.86. The company had revenue of $5.78 billion during the quarter, compared to the consensus estimate of $5.49 billion. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. AstraZeneca’s revenue was up 3.4% compared to the same quarter last year. During the same period last year, the firm earned $1.21 earnings per share. equities research analysts anticipate that AstraZeneca plc will post 1.67 EPS for the current year.
The company also recently announced a semiannual dividend, which will be paid on Monday, March 19th. Shareholders of record on Friday, February 16th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Thursday, February 15th. This represents a yield of 5.62%. AstraZeneca’s dividend payout ratio (DPR) is 57.81%.
TRADEMARK VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/24/9417-shares-in-astrazeneca-plc-azn-purchased-by-synovus-financial-corp.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.